Sara Marrie

Sara Marrie serves as a key procurement lead within the FDA Office of the Commissioner, supporting the Agency’s mission to advance public health through evidence-based regulatory science and policy analysis. She manages acquisitions focused on generating actionable regulatory intelligence, conducting economic impact assessments, and strengthening data-driven decision-making infrastructure. Her portfolio centers on high-value analytical services that inform policy development, including market research, public opinion polling, and specialized data analytics to evaluate the societal and economic implications of FDA regulations. She ensures that contracting activities align with the Office’s strategic priorities in regulatory science and risk communication. Marrie collaborates with a broad range of professional services firms specializing in behavioral research, policy evaluation, and statistical analysis. While no single contractor dominates her portfolio, she consistently engages vendors with demonstrated expertise in survey methodology, econometric modeling, and public health communications. Her working relationships are characterized by a preference for firms with deep domain knowledge in regulatory affairs and public policy, fostering long-term partnerships built on methodological rigor and analytical transparency. Marrie’s contracting patterns reflect a strong orientation toward open competition, with 100% of her acquisitions awarded without set-aside designations. This reflects a strategic focus on accessing the broadest possible pool of qualified expertise rather than prioritizing socioeconomic categories, indicating a mission-driven emphasis on technical capability over socioeconomic preferences. Her primary procurement focus lies in NAICS 541910 (Marketing Research and Public Opinion Polling) and NAICS 519190 (All Other Information Services), underscoring her specialization in collecting and analyzing public sentiment, stakeholder feedback, and regulatory impact data. She procures services that support the development of communication strategies, consumer behavior studies, and policy simulation models—critical tools for ensuring FDA decisions are grounded in real-world evidence and public needs.